Henan Lingrui Pharmaceutical Co., Ltd. (SHA:600285)

SHA:600285 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	3,613	3,501	3,307	2,998	2,690	2,328
Other Revenue	-	-	3.98	3.44	3.48	3.44
Revenue	3,613	3,501	3,311	3,002	2,694	2,332
Revenue Growth (YoY)	5.26%	5.72%	10.31%	11.45%	15.52%	8.09%
Cost of Revenue	861.88	846.56	888.53	837.53	707.97	547.68
Gross Profit	2,751	2,654	2,423	2,164	1,986	1,784
Selling, General & Admin	1,823	1,764	1,675	1,608	1,483	1,342
Research & Development	133.93	131.53	109.65	125.07	86.21	97.76
Other Operating Expenses	1.37	1.74	44.84	40.54	37.4	28.4
Operating Expenses	1,958	1,897	1,834	1,775	1,609	1,468
Operating Income	792.39	757.42	588.93	389.07	376.45	316.2
Interest Expense	-	-	-0.2	-1.14	-1.9	-1.1
Interest & Investment Income	45.49	40.21	55.87	86.61	43.03	57.89
Currency Exchange Gain (Loss)	-	-	-0.01	0	-0	0
Other Non Operating Income (Expenses)	23.74	30.44	-1.69	-1.75	-1.7	7.08
EBT Excluding Unusual Items	861.62	828.07	642.9	472.79	415.88	380.07
Impairment of Goodwill	-	-	-	-	-	-0.5
Gain (Loss) on Sale of Investments	-1.12	-0.01	0.12	5.93	0.05	-0.05
Gain (Loss) on Sale of Assets	0.42	0.01	-0.63	-0.1	-20.32	-2.95
Asset Writedown	-0.5	-0.5	-1.83	-	-	-27.8
Other Unusual Items	-	-	12.49	38.42	17.74	15.43
Pretax Income	860.42	827.57	653.04	517.03	413.35	364.2
Income Tax Expense	111.43	104.99	84.93	51.73	50.85	39.82
Earnings From Continuing Operations	748.99	722.58	568.12	465.3	362.5	324.38
Minority Interest in Earnings	-0	-0.03	-0.01	-0	-0.96	1.11
Net Income	748.99	722.55	568.11	465.3	361.54	325.49
Net Income to Common	748.99	722.55	568.11	465.3	361.54	325.49
Net Income Growth	21.94%	27.18%	22.09%	28.70%	11.08%	10.55%
Shares Outstanding (Basic)	563	561	561	557	556	568
Shares Outstanding (Diluted)	564	564	566	568	567	568
Shares Change (YoY)	-0.32%	-0.42%	-0.30%	0.26%	-0.24%	-1.22%
EPS (Basic)	1.33	1.29	1.01	0.84	0.65	0.57
EPS (Diluted)	1.33	1.28	1.00	0.82	0.64	0.57
EPS Growth	22.32%	27.72%	22.47%	28.37%	11.34%	11.91%
Free Cash Flow	828.16	760.75	792.23	807.92	768.78	378.71
Free Cash Flow Per Share	1.47	1.35	1.40	1.42	1.36	0.67
Dividend Per Share	-	-	0.800	0.600	0.500	0.400
Dividend Growth	-	-	33.33%	20.00%	25.00%	33.33%
Gross Margin	76.14%	75.82%	73.17%	72.10%	73.72%	76.51%
Operating Margin	21.93%	21.63%	17.78%	12.96%	13.98%	13.56%
Profit Margin	20.73%	20.64%	17.16%	15.50%	13.42%	13.96%
Free Cash Flow Margin	22.93%	21.73%	23.92%	26.91%	28.54%	16.24%
EBITDA	863.11	829.16	664.74	463.4	447.63	384.66
EBITDA Margin	23.89%	23.69%	20.07%	15.44%	16.62%	16.50%
D&A For EBITDA	70.72	71.74	75.81	74.33	71.18	68.46
EBIT	792.39	757.42	588.93	389.07	376.45	316.2
EBIT Margin	21.93%	21.63%	17.78%	12.96%	13.98%	13.56%
Effective Tax Rate	12.95%	12.69%	13.00%	10.01%	12.30%	10.93%
Revenue as Reported	-	-	3,311	3,002	2,694	2,332
Advertising Expenses	-	-	265.07	295.91	-	356.56

Source: S&P Global Market Intelligence. Standard template. Financial Sources.